This also supports the DMD trial, with more data showing how ATL1102 is effective against cd49 over expression. This is what we need.
This controlling of cd49 is why ATL1102 is becoming a platform drug. The inflammation caused by the over expression of cd49 is becoming to be seen as one of the root causes to many diseases. Controlling this allows the body a chance of repairing itself. This can be seen by the reduction of fat tissue in muscle of the DMD boy group. And also the reduction of brain lesions in theMS trial group.
- Forums
- ASX - By Stock
- PER
- Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-40
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38503 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 194063 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.099 |
2 | 108491 | 0.098 |
1 | 30927 | 0.097 |
1 | 10004 | 0.096 |
3 | 162157 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 194063 | 5 |
0.110 | 254663 | 3 |
0.115 | 1334300 | 6 |
0.120 | 381142 | 9 |
0.125 | 110429 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
PER (ASX) Chart |